Skip to main content
Premium Trial:

Request an Annual Quote

Feinstein Institutes for Medical Research Wins $2.9M NIH Grant to Study Polygenic Embryo Screening

NEW YORK — The Feinstein Institutes for Medical Research on Monday said that it has received a $2.9 million grant from the National Institutes of Health to research the effects and implications of polygenic embryo screening.

While preimplantation genetic screening is widely used to avoid the implantation of embryos with rare monogenic disease-causing alleles or aneuploidies, PES uses polygenic risk scores to determine complex phenotypes, and the accuracy of such scores in the context of embryo screening is not well understood.

With the four-year grant, Feinstein researchers and collaborators from the Hebrew University of Jerusalem and Baylor College of Medicine will use a combination of simulated and real-world data to determine the ability of PES to reduce the risk of disease under varying conditions. The investigators will use in-depth interviews and a large-scale survey with reproductive clinicians and geneticists to understand the perspectives of those who administer PES.

"The use of polygenic embryo selection has been proposed as one tool to reduce the burden of disease in future generations," Todd Lencz, a Feinstein Institutes researcher and principal investigator of the grant, said in a statement. "With support from the NIH, we will be able to explore the ethical and scientific concerns and better understand the limitations PES may have."

The Scan

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.